One target for such inhibition, the p38 mitogen-activated protein kinase (MAPK) signaling cascade, has a role in inflammation by mediating the cellular response to stress, pathogens, and cytokines.

A recent study has uncovered the essential roles of two proteoglycans, biglycan and decorin, in maintaining bone mass, water ...

Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ...

Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe ...

Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe ...

Discover Trametinib as a promising treatment for severe hypertrophic cardiomyopathy in children with RASopathies.